A detailed explanation of the potential side effects of molotinib (Ojjaara)

Molotinib (trade name: Ojjaara), as a new generation of kinase inhibitors, has shown its unique efficacy in the treatment of myelofibrosis. However, any drug may be accompanied by certain side effects, and molotinib is no exception. This article will detail the possible side effects of molotinib.

Digestive reactions are a common side effect among molotinib users. Patients may experience nausea, vomiting, and diarrhea. These reactions often result from the drug's direct effect on the gastrointestinal tract, but are usually temporary and mild. In order to alleviate these discomforts, patients can try to adjust their diet by eating small meals more frequently and choosing lighter foods.

In terms of hematology, molotinib may cause thrombocytopenia and bleeding tendency. This may be related to the inhibitory effect of the drug on bone marrow function. Therefore, patients should have regular blood tests during medication to detect and respond to these potential blood problems in a timely manner.

In addition, molotinib may cause milder symptoms such as fatigue and dizziness. Although these symptoms usually do not seriously affect the patient's daily life, if symptoms persist or worsen, a doctor should be consulted promptly.

More seriously, the use of molotinib may be associated with liver problems, manifesting as symptoms such as fatigue, loss of appetite, jaundice, and right upper quadrant pain. These symptoms may indicate that the drug has caused some damage to the liver, and the patient needs to seek medical attention immediately for detailed examination. Also, molotinib may increase the risk of cardiovascular events, such as heart attack or stroke. If severe symptoms such as chest pain and difficulty breathing occur, patients should seek emergency medical help immediately.

In addition to the above side effects, molotinib may also cause venous thrombosis, which may manifest as leg swelling, pain, or tenderness, as well as sudden chest pain and shortness of breath. These symptoms require patients to be highly vigilant and seek immediate medical attention.

In addition, infection is a special concern during molotinib treatment. Because the drug may affect the normal function of the immune system, patients may be more susceptible to infections while taking molotinib. Therefore, it is important to maintain good personal hygiene and avoid direct contact with sources of infection. Once infection symptoms such as fever and cough occur, patients should seek medical treatment immediately.

In summary, molotinib has significant efficacy in the treatment of myelofibrosis, but it may also be accompanied by a series of potential side effects. In order to ensure the safety and effectiveness of the medication, patients should closely monitor their physical condition during use, undergo relevant examinations regularly, and maintain close communication with the medical team.